


Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 02/01/2022
Policy Number: PA.CP.PHAR.415	Effective Date: 01/01/2018 Revision Date: 01/2022
Policy Name: Ravulizumab-cwvz (Ultomiris)	
<p>Type of Submission – <u>Check all that apply:</u></p> <ul style="list-style-type: none"> <input type="checkbox"/> New Policy <input checked="" type="checkbox"/> Revised Policy* <input type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> 	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any changes or clarifying information for the policy below:</p> <p>1Q 2022 annual reviewed: RT4: updated age and dosing requirements for PNH per FDA pediatric expansion (from age at least 18 years to age at least 1 month); for PNH, added requirement for no concurrent use with Empaveli; added amyotrophic lateral sclerosis to section III as an indication not covered due to lack of efficacy; references reviewed and updated.</p>	
Name of Authorized Individual (Please type or print): Venkateswara R. Davuluri, MD	Signature of Authorized Individual: 

Clinical Policy: Ravulizumab-cwvz (Ultomiris)

Reference Number: PA.CP.PHAR.415

Effective Date: 04.2019

Last Review Date: 01.2022

[Coding Implications](#)
[Revision Log](#)

Description

Ravulizumab-cwvz (Ultomiris™) is a complement inhibitor.

FDA Approved Indication(s)

Ultomiris is indicated for the treatment of:

- Adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH)
- Adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA)

Limitation(s) of use: Ultomiris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health & Wellness® that Ultomiris is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Paroxysmal Nocturnal Hemoglobinuria (must meet all):

1. Diagnosis of PNH;
2. Prescribed by or in consultation with a hematologist;
3. Age \geq 18 years;
4. Flow cytometry shows detectable glycosylphosphatidylinositol (GPI)-deficient hematopoietic clones or \geq 5% PNH cells;
5. Member meets one of the following (a or b):
 - a. History of \geq 1 transfusion in the past 24 months and (i or ii):
 - i. Documentation of hemoglobin $<$ 7 g/dL in members without anemia symptoms;
 - ii. Documentation of hemoglobin $<$ 10 g/dL in members with anemia symptoms;
 - b. History of thrombosis;
6. Ultomiris is not prescribed concurrently with Empaveli™ or Soliris®;
7. Dose does not exceed the following (a, b, and c):
 - a. Loading dose on Day 1:
 - i. Weight \geq 5 to $<$ 10 kg: 600 mg;
 - ii. Weight \geq 10 to $<$ 20 kg: 600 mg;
 - iii. Weight \geq 20 to $<$ 30 kg: 900 mg;
 - iv. Weight \geq 30 to $<$ 40 kg: 1,200 mg;

- v. Weight ≥ 40 to < 60 kg: 2,400 mg;
- vi. Weight ≥ 60 to < 100 kg: 2,700 mg;
- vii. Weight ≥ 100 kg: 3,000 mg;
- b. If member is switching therapy from Soliris, administration of the loading dose should occur 2 weeks after the last Soliris infusion;
- c. Maintenance dose on Day 15 and at the specified frequency thereafter:
 - i. Weight ≥ 5 to < 10 kg: 300 mg every 4 weeks;
 - ii. Weight ≥ 10 to < 20 kg: 600 mg every 4 weeks;
 - iii. Weight ≥ 20 to < 30 kg: 2,100 mg every 8 weeks;
 - iv. Weight ≥ 30 to < 40 kg: 2,700 mg every 8 weeks;
 - v. Weight ≥ 40 to < 60 kg: 3,000 mg every 8 weeks;
 - vi. Weight ≥ 60 to < 100 kg: 3,300 mg every 8 weeks;
 - vii. Weight ≥ 100 kg: 3,600 mg every 8 weeks.

Approval duration: 6 months

B. Atypical Hemolytic Uremic Syndrome (must meet all):

- 1. Diagnosis of aHUS (i.e., complement-mediated HUS);
- 2. Prescribed by or in consultation with a hematologist or nephrologist;
- 3. Age ≥ 1 month;
- 4. Member has signs of TMA as evidenced by all of the following (a, b, and c):
 - a. Platelet count $\leq 150 \times 10^9/L$;
 - b. Hemolysis such as an elevation in serum lactate dehydrogenase (LDH);
 - c. Serum creatinine above the upper limits of normal or member requires dialysis;
- 5. Documentation that member does not have either of the following:
 - a. A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency;
 - b. STEC-HUS;
- 6. Ultomiris is not prescribed concurrently with Soliris;
- 7. Dose does not exceed the following (a, b, and c):
 - a. Loading dose on Day 1:
 - i. Weight ≥ 5 to < 10 kg: 600 mg;
 - ii. Weight ≥ 10 to < 20 kg: 600 mg;
 - iii. Weight ≥ 20 to < 30 kg: 900 mg;
 - iv. Weight ≥ 30 to < 40 kg: 1,200 mg;
 - v. Weight ≥ 40 to < 60 kg: 2,400 mg;
 - vi. Weight ≥ 60 to < 100 kg: 2,700 mg;
 - vii. Weight ≥ 100 kg: 3,000 mg;
 - b. If member is switching therapy from Soliris, administration of the loading dose should occur 2 weeks after the last Soliris infusion;
 - c. Maintenance dose on Day 15 and at the specified frequency thereafter:
 - i. Weight ≥ 5 to < 10 kg: 300 mg every 4 weeks;
 - ii. Weight ≥ 10 to < 20 kg: 600 mg every 4 weeks;
 - iii. Weight ≥ 20 to < 30 kg: 2,100 mg every 8 weeks;
 - iv. Weight ≥ 30 to < 40 kg: 2,700 mg every 8 weeks;
 - v. Weight ≥ 40 to < 60 kg: 3,000 mg every 8 weeks;
 - vi. Weight ≥ 60 to < 100 kg: 3,300 mg every 8 weeks;

vii. Weight \geq 100 kg: 3,600 mg every 8 weeks.

Approval duration: 6 months

C. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters (a or b):
 - a. PNH:
 - i. Improved measures of intravascular hemolysis (e.g., normalization of LDH);
 - ii. Reduced need for red blood cell transfusions;
 - iii. Increased or stabilization of hemoglobin levels;
 - iv. Less fatigue;
 - v. Improved health-related quality of life;
 - vi. Fewer thrombotic events;
 - b. aHUS:
 - i. Improved measures of intravascular hemolysis (e.g., normalization of LDH);
 - ii. Increased or stabilized platelet counts;
 - iii. Improved or stabilized serum creatinine or estimated glomerular filtration rate (eGFR);
 - iv. Reduced need for dialysis;
3. Ultomiris is not prescribed concurrently with (a or b):
 - a. PNH: Empaveli or Soliris;
 - b. aHUS: Soliris;
4. If request is for a dose increase, new dose does not exceed one of the following (a or b):
 - a. PNH:
 - i. Weight \geq 40 to $<$ 60 kg: 3,000 mg every 8 weeks;
 - ii. Weight \geq 60 to $<$ 100 kg: 3,300 mg every 8 weeks;
 - iii. Weight \geq 100 kg: 3,600 mg every 8 weeks;
 - b. aHUS:
 - i. Weight \geq 5 to $<$ 10 kg: 300 mg every 4 weeks;
 - ii. Weight \geq 10 to $<$ 20 kg: 600 mg every 4 weeks;
 - iii. Weight \geq 20 to $<$ 30 kg: 2,100 mg every 8 weeks;
 - iv. Weight \geq 30 to $<$ 40 kg: 2,700 mg every 8 weeks;
 - v. Weight \geq 40 to $<$ 60 kg: 3,000 mg every 8 weeks;
 - vi. Weight \geq 60 to $<$ 100 kg: 3,300 mg every 8 weeks;
 - vii. Weight \geq 100 kg: 3,600 mg every 8 weeks.

Approval duration: 6 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – PA.CP.PMN.53 for Medicaid or evidence of coverage documents.
- B. Amyotrophic lateral sclerosis.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ADAMTS13: a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13

aHUS: atypical hemolytic uremic syndrome

FDA: Food and Drug Administration

GPI: glycosyl phosphatidylinositol

LDH: lactate dehydrogenase

PNH: paroxysmal nocturnal hemoglobinuria

STEC-HUS: Shiga toxin E. coli related hemolytic uremic syndrome

TMA: thrombotic microangiopathy

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): patients with unresolved *Neisseria Meningitidis* infection; patients who are not currently vaccinated against *Neisseria meningitidis*, unless the risks of delaying Ultomiris treatment outweigh the risks of developing a meningococcal infection
- Boxed warning(s): serious meningococcal infections

Appendix D: General Information

- Ultomiris is only available through a REMS (Risk Evaluation and Mitigation Strategy) program due to the risk of life-threatening and fatal meningococcal infection. Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Ultomiris and revaccinated according to current medical guidelines for vaccine use. Patients should be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics if necessary.
- Examples of symptoms of anemia include but are not limited to: dizziness or lightheadedness, fatigue, pale or yellowish skin, shortness of breath, chest pain, cold hands and feet, and headache.

- Ultomiris is a humanized monoclonal antibody to complement component C5 that was engineered from Soliris. It is virtually identical to Soliris but has a longer half-life that allows for less frequent dosing intervals.
- In August 2021, Alexion announced it is discontinuing the global CHAMPION-ALS phase 3 clinical study of Ultomiris in adults with amyotrophic lateral sclerosis due to an interim data review showing a lack of efficacy.

V. Dosage and Administration

Dosage and Administration				
Indication	Dosing Regimen*			Maximum Dose
PNH, aHUS	Body Weight Range (kg)	Loading Dose (mg)	Maintenance Dose (mg)	3,600 mg/ 8 weeks
	≥ 5 to < 10	600	300 every 4 weeks	
	≥ 10 to < 20	600	600 every 4 weeks	
	≥ 20 to < 30	900	2,100 every 8 weeks	
	≥ 30 to < 40	1,200	2,700 every 8 weeks	
	≥ 40 to < 60	2,400	3,000 every 8 weeks	
	≥ 60 to < 100	2,700	3,300 every 8 weeks	
	≥ 100	3,000	3,600 every 8 weeks	
	Day 1: Loading dose IV Day 15 and thereafter: Maintenance dose IV			

**For patients switching from eculizumab to Ultomiris, administer the loading dose of Ultomiris IV 2 weeks after the last eculizumab infusion, and then administer maintenance doses IV once at the specified frequency, starting 2 weeks after loading dose administration.*

VI. Product Availability

Single-dose vials: 300 mg/30 mL, 300 mg/3 mL, 1,100 mg/11 mL

VII. References

1. Ultomiris Prescribing Information. Boston, MA: Alexion Pharmaceuticals, Inc.; June 2021. Available at: www.ultomiris.com. Accessed September 15, 2021.
2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106(12):3699-3709. doi:10.1182/blood-2005-04-1717.
3. Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016; 31: 15-39.
4. AstraZeneca. Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotrophic lateral sclerosis. Press release published August 20, 2021. Available at: <https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-ultomiris-phase-iii-als-trial.html>. Accessed September 15, 2021.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1303	Injection, ravulizumab-cwvz, 300 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created.	04/2019	
1Q 2020 annual review: added language to clarify timing of loading dose when switching from Soliris; criteria added for new FDA indication: aHUS; references reviewed and updated.	01/2020	
1Q 2021 annual review: added requirement against concurrent use with Soliris; added new strength vials- 300 mg/3 mL and 1,100 mg/11 mL; references reviewed and updated.	01/2021	
1Q 2022 annual reviewed: RT4: updated age and dosing requirements for PNH per FDA pediatric expansion (from age at least 18 years to age at least 1 month); for PNH, added requirement for no concurrent use with Empaveli; added amyotrophic lateral sclerosis to section III as an indication not covered due to lack of efficacy; references reviewed and updated.	01/2022	